FDA Approves corcept's mifepristone for Cushing's syndrome

Source: China Council for the promotion of drugs (2012-02-20) US regulatory agency gave a green light to corcept's korlym (mifepristone) therapy, which is the first drug approved by FDA for the treatment of Cushing's syndrome Korlym is also the company's first public offering After the announcement, the stock price of corcept company increased by more than 40% The approved new drug korlym can block the activity of corticosteroids In patients with Cushing's syndrome, the adrenal gland secretes too much corticosteroids, which causes high blood pressure The FDA says korlym works by blocking hormone receptor binding Korlym is the latest example of the current drug development model for rare diseases, which shows that the development and treatment of a very small group of patients - with very few clinical trial results can also be approved by FDA Korlym was approved as an orphan drug in 2007 and is expected to benefit about 5000 patients in the United States Korlym's FDA approval was based on a clinical trial of only 50 patients Because of the use of an ingredient in abortion drugs, korlym has a warning for pregnant women According to Bloomberg, corcept believes that the presence of the ingredient may limit korlym's use Large and small biopharmaceutical organizations hope to research in the field of rare diseases It not only helps patients whose medical needs are not met, but also has the advantages of prolonging exclusive cycle and low cost of clinical development Original link: http://www.finebiotech.com/story/concept-skylocks-fda-nod-rare-disease-drug/2012-02-17